TickerBrief

NVO · Novo Nordisk A/S

Novo Nordisk A/S NVO

Develops and manufactures pharmaceuticals for diabetes and obesity, including insulin and GLP-1 treatments.

Industry
Pharmaceuticals
Listed on
OMX NORDIC EXCHANGE COPENHAGEN A/S
IPO
1974-05-17
Website
novonordisk.com

Daily brief

Novo Nordisk falls despite earnings beat as pipeline concerns persist

+0.56% to $44.53 from $44.28

What moved NVO

  • Adjusted sales grew 7% in the second quarter, led by GLP-1 and obesity franchise growth, with adjusted sales rising to DKK 78.49 billion.
  • The Wegovy pill saw rapid uptake globally, and the company raised its 2026 guidance.
  • Shares fell despite the beat and raised outlook, weighed down by pipeline setbacks and increasing competition from Eli Lilly.
  • The company continues to face headwinds from patent expiry and U.S. pricing pressure.

Sources: Yahoo Finance

← All stocks

This content is for informational purposes only and is not investment advice. Always do your own research before making financial decisions.